Erythropoietin and its receptor in breast cancer: Putting together the pieces of the puzzle

Oncologist

Volumn 13, Issue 7, 2008, Pages 761-768

  Mannello, Ferdinando ^a   Tonti, Gaetana A M ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Breast cancer; Cancer related anemia; Epo EpoR homo and heterodimeric complex; Erythropoietin; Erythropoietin receptor; JAK2 signaling

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN;

ANEMIA; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; COMPLEX FORMATION; HUMAN; INTERNALIZATION; OVERALL SURVIVAL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANEMIA; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; JANUS KINASE 2; PARACRINE COMMUNICATION; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 48749089984     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0110     Document Type: Review

References (54)

1. Jelkmann W. Erythropoietin after a century of research: Younger than ever. Eur J Haematol 2007;78:183-205.
2. Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-488.
3. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007;1776:1-9.
4. Farrell F, Lee A. The erythropoietin receptor and its expression in tumour cells and other tissues. The Oncologist 2004;9(suppl 5):18-30.
5. Yoshimura A, Arai K. Physician education: The erythropoietin receptor and signal transduction. The Oncologist 1996;1:337-339.
6. Jubinsky PT, Krijanovski OI, Nathan DG et al. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997;90:1867-1873.
7. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-14912.
8. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007;19:634-645.
9. Hardee ME, Arcasoy MO, Blackwell KL et al. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-339.
10. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001;8:1327-1338.
11. Goldrich A, Olivotto IA, Alexander CS et al. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol 2007;14:227-233.
12. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. The Oncologist 2007;12:362-365.
13. Blau CA. Erythropoietin in cancer: Presumption of innocence? STEM CELLS 2007;25:2094-2097.
14. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
15. Henke M, Mattern D, Pajonk F. In reply [letter]. J Clin Oncol 2007;25:1815.
16. Phillips TM, Kim K, Vlashi E et al. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007;9:1122-1129.
17. Acs G, Zhang PJ, Rebbeck TR et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:969-981.
18. Arcasoy MO, Amin K, Karayal AF et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918.
19. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
20. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-1895.
21. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: Erythropoietin has multiple actions. STEM CELLS 2002;20:485-492.
22. Juul SE, Zhao Y, Dame JB et al. Origin and fate of erythropoietin in human milk. Pediatr Res 2000;48:660-667.
23. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565.
24. Pelekanou V, Kampa M, Kafousi M et al. Erythropoietin and its receptor in breast cancer: Correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 2007;16:2016-2023.
25. Mannello F, Fabbri L, Ciandrini E et al. Enhanced levels of erythropoietin in nipple aspirate fluid and in ductal cells from breast cancer patients. Cell Oncol 2008;30:51-61.
26. Wincewicz A, Sulkowska M, Koda M et al. STAT3, HIF-1α, EPO and EPOR-signaling proteins in human primary ductal breast cancers. Folia Histochem Cytobiol 2007;45:81-86.
27. LaMontagne KR, Butler J, Marshall DJ et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;5:347-355.
28. Della Ragione F, Cucciolla V, Borriello A et al. Erythropoietin receptors on cancer cells: A still open question [letter]. J Clin Oncol 2007;25:1812-1813; author reply 1815.
29. Österborg A, Aapro M, Cornes P et al. Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510-519.
30. Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007;(395):pe38.
31. Pajonk F, Weil A, Sommer A et al. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 2004;23:8987-8991.
32. Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and fiction-more careful studies are needed [letter]. J Clin Oncol 2007;25:1813-1814.
33. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: Structure, activation and intracellular signal transduction. Trends Endocrinol Metab 1999;10:18-23.
34. Rossert J, Eckardt KU. Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol Dial Transplant 2005;20:1025-1028.
35. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006;70:246-250.
36. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
37. Kennedy J, Buchan AM. C-EPO: Ready for prime-time preconditioning [letter]? Cerebrovasc Dis 2005;19:272-273.
38. Elliott S, Egrie J, Browne J et al. Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol 2004;32:1146-1155.
39. Kwon DN, Song H, Park JY et al. Dynamic control of oligosaccharide modification in the mammary gland: Linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO. Transgenic Res 2006;15:37-55.
40. Acs G, Chen M, Xu X et al. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004;214:243-251.
41. Verdier F, Walrafen P, Hubert N et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000;275:18375-18381.
42. Walrafen P, Verdier F, Kadri Z et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005;105:600-608.
43. Meyer L, Deau B, Forejtnikova H et al. beta-Trcp mediates ubiquitination and degradation of erythropoietin receptor and controls cell proliferation. Blood 2007;109:5215-5222.
44. Beckman DL, Lin LL, Quinones ME et al. Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. Blood 1999;94:2667-2675.
45. Gewirtz DA, Di X, Walker TD et al. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumour drugs. Clin Cancer Res 2006;12:2232-2238.
46. Bohnen RF, Banisadre M, Gulbrandson RN et al. Erythrocytosis caused by an erythropoietin-producing breast adenocarcinoma. West J Med 1990;152:417-418.
47. Yasuda Y, Fujita Y, Masuda S et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-1805.
48. Kling PJ. Roles of erythropoietin in human milk. Acta Paediatr Suppl 2002;91:31-35.
49. Friedman AD, Nimbalkar D, Quelle FW. Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation. J Biol Chem 2003;278:26851-26861.
50. Lester RD, Jo M, Campana WM et al. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in the migration observed in hypoxia. J Biol Chem 2005;280:39273-39277.
51. Hardee ME, Rabbani ZN, Arcasoy MO et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006;5:356-361.
52. Lai S, Grandis JR. Understanding the presence and function of erythropoietin receptor on cancer cells [letter]. J Clin Oncol 2006;24:4675-4676.
53. Burton A. Is it all over for erythropoietin? [letter]. Lancet Oncol 2007;8:285.
54. Guan X, Chen L. Role of erythropoietin in cancer-related anaemia: A double-edged sword? J Int Med Res 2008;36:1-8.